The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis
Abstract
For most warfarin indications, the target maintenance international normalised ratio (INR) is 2-3. Risk factors for bleeding complications with warfarin use include age, history of past bleeding and specific comorbid conditions. To reverse the effects of warfarin, vitamin K(1) can be given. Immediate reversal is achieved with a prothrombin complex concentrate (PCC) and fresh frozen plasma (FFP). Vitamin K(1) is essential for sustaining the reversal achieved by PCC and FFP. When oral vitamin K(1) is used for warfarin reversal, the injectable formulation of vitamin K(1) is preferable to tablets because of its flexible dosing; this formulation can be given orally or injected. To temporarily reverse the effect of warfarin when there is a need to continue warfarin therapy, vitamin K(1) should be given in a dose that will quickly lower the INR to a safe, but not subtherapeutic, range and will not cause resistance once warfarin is reinstated. Prothrombinex-HT is the only PCC approved in Australia and New Zealand for warfarin reversal. It contains factors II, IX and X, and low levels of factor VII. FFP should be added to Prothrombinex-HT as a source of factor VII when used for warfarin reversal. Simple dental or dermatological procedures may not require interruption to warfarin therapy. If necessary, warfarin therapy can be withheld 5 days before elective surgery, when the INR usually falls to below 1.5 and surgery can be conducted safely. Bridging anticoagulation therapy for patients at high risk for thromboembolism should be undertaken in consultation with the relevant experts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540120077042 · Cited by 2,371
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Fugh-Berman, A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06457-0 · Cited by 1,099
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003) · Circulation · doi:10.1161/01.cir.0000063575.17904.4e · Cited by 911
(2006) · Pharmacodynamic Basis of Herbal Medicine, Second Edition · doi:10.1201/9781420006452.ch4 · Cited by 905
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Cited by
Hemphill, J. C., Greenberg, S. M., Anderson, C. S., Becker, K., Bendok, B. R., Cushman, M., Fung, G. L., Goldstein, J. N., Macdonald, R. L., Mitchell, P. H., et al. (2015) · Stroke · doi:10.1161/str.0000000000000069 · Cited by 3,994
Morgenstern, L. B., Hemphill, J. C., Anderson, C., Becker, K., Broderick, J. P., Connolly, E. S., Greenberg, S. M., Huang, J. N., Macdonald, R. L., Messé, S. R., et al. (2010) · Stroke · doi:10.1161/str.0b013e3181ec611b · Cited by 1,496
Broderick, J., Connolly, S., Feldmann, E., Hanley, D., Kase, C., Krieger, D., Mayberg, M., Morgenstern, L., Ogilvy, C. S., Vespa, P., et al. (2007) · Stroke · doi:10.1161/strokeaha.107.183689 · Cited by 1,125
Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
The Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830
Metadata
- Authors
- Baker, R. I., Coughlin, P. B., Salem, H. H., Gallus, A. S., Harper, P. L., & Wood, E. M.
- Venue
- Medical Journal of Australia
- Publisher
- AMPCo
- Published
- 2004-11
- Volume
- 181
- Issue
- 9
- Pages
- 492-497
- ISSN
- 0025-729X (ISSN-L)
- 1326-5377
- OpenAlex
- W2163334011
- Cited by
- 309
- References
- 27
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. https://app.cochat.ai/papers/10.5694/j.1326-5377.2004.tb06407.x
- The paper
- Baker, R. I., Coughlin, P. B., Salem, H. H., Gallus, A. S., Harper, P. L., & Wood, E. M. (2004). Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2004.tb06407.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.